BioVie Inc Ordinary Shares - Class A BIVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.27
- Day Range
- $1.58–2.25
- 52-Week Range
- $1.06–9.09
- Bid/Ask
- $1.66 / $1.80
- Shares Outstanding
- 7.54M
- Market Cap
- $12.37M
- Volume/Avg
- 1,445 / 141,531
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.bioviepharma.com
Valuation
|
Metric
|
BIVI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.79 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIVI
|
|---|---|
Quick Ratio | 9.02 |
Current Ratio | 9.97 |
Interest Coverage | −1,088.49 |
Quick Ratio
BIVI
Profitability
|
Metric
|
BIVI
|
|---|---|
Return on Assets (Normalized) | −73.71% |
Return on Equity (Normalized) | −82.82% |
Return on Invested Capital (Normalized) | −84.80% |
Return on Assets
BIVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&L@w&#? | LOCK|#tz^^ | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|n%$#&ll | LOCK|&&nwp | $70B | |||
| argenx SE ADR
ARGX
| LOCK|?thf%hS | LOCK|$^% | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n>kD<X | LOCK|>PjmB | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H$%&R& | LOCK|VK | $36B | |||
| Moderna Inc
MRNA
| LOCK|Y&TFwH | LOCK|b< | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|qQTGw%B | LOCK|J%vD | $25B | |||
| Incyte Corp
INCY
| LOCK|fK$^Q$ | LOCK|p% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|cByS^S% | LOCK|Q& | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|jqvHbl | LOCK|Pz | $16B |
United States